Quick Dispatch:
Your tirzepatide surmount SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surmount SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes ships.
Need Help?
Questions about tirzepatide surmount SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surmount SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes in your area.
SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized,
28.59
Tirzepatide lowers body weight for adults with obesity, regardless of disease duration
27.19
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
29.76
ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction
20.39
Tirzepatide not linked to increased risk for depression
26.98
Did Tirzepatide Steal the Show at EASD?
27.53
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://ja.ma/4pADUmu
21.20
